Elders And 2 Other Undervalued Small Caps With Insider Action In Australia

Amidst a generally buoyant Australian market where the ASX200 recently closed up by 0.9%, all sectors except IT showed positive movement. This environment, coupled with anticipations of a U.S Federal Reserve rate cut, creates an interesting backdrop for exploring undervalued opportunities within the small-cap space. In this context, understanding what constitutes a good stock can be pivotal; factors such as insider buying can often signal unrecognized value in smaller companies poised for growth.

Top 10 Undervalued Small Caps With Insider Buying In Australia

Name	PE	PS	Discount to Fair Value	Value Rating
Corporate Travel Management	17.9x	2.7x	46.32%	★★★★★★
Nick Scali	14.5x	2.7x	42.18%	★★★★★☆
RAM Essential Services Property Fund	NA	5.8x	38.95%	★★★★★☆
Healius	NA	0.6x	42.03%	★★★★★☆
Eagers Automotive	9.6x	0.3x	33.51%	★★★★☆☆
Elders	22.0x	0.5x	45.59%	★★★★☆☆
Codan	29.2x	4.3x	26.60%	★★★★☆☆
Tabcorp Holdings	NA	0.7x	18.78%	★★★★☆☆
Dicker Data	22.4x	0.8x	-1.66%	★★★☆☆☆
Coventry Group	300.4x	0.5x	-11.85%	★★★☆☆☆

Click here to see the full list of 24 stocks from our Undervalued ASX Small Caps With Insider Buying screener.

Let's explore several standout options from the results in the screener.

Elders (ASX:ELD)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Elders is an Australian company involved in providing a range of services including branch network operations, wholesale products, feed and processing services, and corporate services, with a market capitalization of approximately A$2.54 billion.

Operations: The entity generates the majority of its revenue from its Branch Network, contributing A$2.54 billion, supplemented by Wholesale Products and Feed and Processing Services at A$341.19 million and A$120.14 million respectively. Over recent periods, it has observed a gross profit margin trend ranging from 16% to 21%, indicating variability in cost management relative to sales revenue across different fiscal quarters.

PE: 22.0x

Elders Limited, a notable player in the Australian market, recently reaffirmed its earnings guidance for FY 2024, projecting an underlying EBIT of A$120 million to A$140 million. Despite a challenging half-year with net income dropping to A$11.59 million from A$48.85 million the previous year, insider confidence remains evident as they recently purchased shares, signaling belief in the company's resilience and growth potential. With new board appointments enhancing leadership and strategic direction, Elders is poised to leverage its industry expertise despite current financial hurdles.

• Get an in-depth perspective on Elders' performance by reading our valuation report here.

• Assess Elders' past performance with our detailed historical performance reports.

Nick Scali (ASX:NCK)

Simply Wall St Value Rating: ★★★★★☆

Overview: Nick Scali is a furniture retailing company with operations primarily focused on selling a range of furniture products.

Operations: Retailing of Furniture generated A$450.45 million, with a gross profit margin peaking at 65.48% in the latest period, reflecting significant efficiency in managing production costs relative to revenue.

PE: 14.5x

Nick Scali Limited, a standout in the market for undervalued entities, has recently fortified its financial position through substantial equity offerings totaling A$60 million at a price of A$13.25 per share. This strategic move, executed in May and April 2024, underscores their proactive approach to capital management. With earnings projected to grow by 8.3% annually, insider confidence is evident as they've recently purchased shares, signaling strong belief in the company's future prospects amidst higher risk funding structures solely reliant on external borrowing.

• Take a closer look at Nick Scali's potential here in our valuation report.

• Understand Nick Scali's track record by examining our Past report.

Neuren Pharmaceuticals (ASX:NEU)

Simply Wall St Value Rating: ★★★★★☆

Overview: Neuren Pharmaceuticals is a company focused on developing pharmaceutical products, with a market capitalization of approximately A$231.94 million.

Operations: Pharmaceutical Products generated A$231.94 million in revenue, with a gross profit margin of 88.47%. Operating expenses for the period amounted to A$5.95 million.

PE: 16.7x

Neuren Pharmaceuticals, a lesser-known yet promising player in the pharmaceutical sector, recently showcased positive Phase 2 trial results for NNZ-2591, targeting Pitt Hopkins syndrome—a condition with no approved treatments. This breakthrough underscores their potential in addressing unmet medical needs. With revenue expected to grow by 10.53% annually, and insider confidence demonstrated through recent share purchases, the company's prospects appear increasingly compelling despite its reliance on higher-risk external borrowing for funding.

• Navigate through the intricacies of Neuren Pharmaceuticals with our comprehensive valuation report here.

• Evaluate Neuren Pharmaceuticals' historical performance by accessing our past performance report.

Turning Ideas Into Actions

• Discover the full array of 24 Undervalued ASX Small Caps With Insider Buying right here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com